Xiamen China, December 9, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) recently signed a Memorandum of Understanding (MoU) on strategic collaboration with The Janssen Pharmaceutical Companies of Johnson & Johnson. In this cooperation, both parties will work together to drive the innovative pharmaceutical ecosystem, with the aim of continuously optimizing the full life cycle of drugs, empowering patients to manage the whole course of disease, improving patients’ benefits, and facilitating progress toward “Healthy China 2030”.
According to the MoU, both parties will jointly build a collaborative innovation service model from end to end, covering market access, doctor-patient education, research and development of new biomarkers, and construction of a big data platform. AmoyDx will further empower patients to use management of the whole course of disease and, while improving the accessibility of concomitant diagnosis and accelerating patient reimbursement, it will further optimize the diagnosis of Janssen’s key target therapeutic areas including lung cancer and urothelial cancer.
The partnership will also support patients’ early access to transformational treatment solutions under the country's pilot policies, such as the Plan for the Development of Innovative Regulatory of Drugs and Medical Devices in the Guangdong-Hong Kong-Macao Greater Bay Area that allows medicines approved outside the Chinese mainland to be utilized by doctors.
The cooperation will also drive personalized medicine, the integration of diagnosis and treatment, optimize clinical development programs and explore emerging R&D opportunities to sustain the discovery, development, and delivery of transformational medicines for patients in need.
“As a transformational medical innovator and one of the first multinational pharmaceutical companies in China, Janssen remains imaginative and aggressive in partnering and creating win-win situations to deliver remarkable solutions. We aim to continue creating value for patients, healthcare professionals, and healthcare systems in China and across the globe,” said Jenny Zheng, president of Janssen China.
“Amoy Diagnostics is committed to reaching more innovative medical solutions and assisting in the development of precision diagnosis and treatment in China.” said Li-Mou Zheng, Ph.D., Founder and Chairman of AmoyDx, “Through strategic cooperation with Janssen China, we will work together to accelerate the entry of transformational treatment regimens and contribute to the improvement of patient benefits.”
About Janssen China
Over the past 36 years, Janssen has used innovation to protect health in China and dedicated itself to creating a future without disease. We are a pharmaceutical company under Johnson & Johnson which fights diseases with science, expands access with wisdom, and brings hope with care and love, helping people to enjoy a better tomorrow. We have patients in our hearts, we are driven by innovation, and we focus on the six major diseases that can cause huge changes to human health: Oncology, Immunology, Infectious Diseases and Vaccines, Neuroscience, Cardiovasology and Metabolism, and Pulmonary Arterial Hypertension. Together with many partners, we achieve breakthroughs in medical and health solutions that protect health in China with innovation.
Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on the field of precision medical molecular diagnosis of tumors, specializes in technological innovation that benefits the common people, and is committed to providing patients with rules-compliant, high-quality diagnostic products and services, so that patients can truly benefit from precision medical treatment. Many core technologies and qualifications, such as the National Enterprise Technology Center, National Specialized New “Small Giant” Enterprise, and Postdoctoral Scientific Research Workstation, have been awarded patents from China, US, Japan, and Europe, the National Invention Patent Silver Award, and National Science and Technology Progress Award (Secondary Prize). At present, hundreds of large and medium-sized hospitals in dozens of countries and regions around the world have chosen AmoyDx’ products, which hundreds of thousands of cancer patients benefit from every year. Targeting the source of innovation in the industry and empowering the clinical use of reference listed drugs with concomitant diagnosis, Amoy Diagnostics is a strategic partner for concomitant diagnosis of tumor for many top pharmaceutical companies and an indigenous brand well-known around the world.